Citations 1
Neoadjuvant Study of Niraparib in Patients With HER2-Negative, BRCA-Mutated Resectable Breast Cancer
Liu, Minetta C. , Irie, Hanna Y. , Santa‐Maria, Cesar A. , Reeves, James E., Pan, Peng , Shan, Ming , Tang, Yongqiang , Graham, Julie , Hazard, Sebastien , Isakoff, Steven J. , Spring, Laura , Han, Hyo S , Hamilton, Erika , Santa-Maria, Cesar Augusto , Pan, Peng, Graham, Julie, Ellisen, Leif W.
No container title available | August 6, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available
Abstract This study evaluated neoadjuvant niraparib antitumor activity and safety in patients with localized HER2-negative, BRCA-mutated breast cancer. Twenty-one patients received niraparib 200 mg once daily in 28-day cycles. After 2 cycles, tumor response (≥30% reduction from baseline) by MRI was 90.5% and 40.0% (6/15) of patients who only received niraparib (2–6 cycles) had pathological complete response. No new safety signals were identified and high niraparib intratumoral concentration was observed.